Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
View Patent ↗The present invention relates to cupredoxin, specifically Pseudomonas aeruginosa azurin, and/or Pseudomonas aeruginosa cytochrome C 551 and their use in inhibiting of viral infection, and in particular infection of mammalian cells by the Human Immunodeficiency Virus (HIV). The invention also relates to variants and derivatives of cupredoxin and cytochrome c that retain the ability to inhibit viral infection, and in particular infection by the Human Immunodeficiency Virus (HIV). The invention also relates to research methods for studying viral and bacterial infection in mammalian cells.
1. An isolated peptide consisting of an amino acid sequence selected from the group consisting of residues 36-128 of SEQ ID NO:1, residues 36-88 of SEQ ID NO:1, and residues 88-113 of SEQ ID NO:1, that is capable of binding to one or more targets selected from the group consisting of CD4, gp120, ICAM-3, and DC-SIGN.
2. The isolated peptide of claim 1 , comprising a cupredoxin selected from the group consisting of pseudoazurin, plastocyanin, rusticyanin, Laz and auracyanin.
3. The isolated peptide of claim 2 , wherein the cupredoxin is Laz.
4. The isolated peptide of claim 2 , wherein the cupredoxin is from an organism selected from the group consisting of Alcaligenes faecalis, Achromobacter xylosoxidan, Bordetella bronchiseptica, Methylomonas sp., Neisseria meningitidis, Neisseria gonorrhea, Pseudomonas fluorescens, Pseudomonas chiororaphis, Xylella fastidiosa and Vibrio parahaemolyticus.
5. The isolated peptide of claim 4 , that is from Neisseria gonorrhea.
6. The isolated peptide of claim 1 , which consists of a sequence with at least 90% amino acid sequence identity to residues 36-128 of SEQ ID NO:1.
7. The isolated peptide of claim 1 , wherein the peptide consists of residues 36-128 of SEQ ID NO:1.
8. A composition, comprising at least one peptide of claim 1 in a pharmaceutical composition.
9. The composition of claim 8 , wherein the pharmaceutical composition is formulated for intravenous administration.
10. The composition of claim 8 , wherein the peptide of claim 1 comprises a cupredoxin from an organism selected from the group consisting of Alcaligenes faecalis, Achromobacter xylosoxidan, Bordetella bronchiseptica, Methylomonas sp., Neisseria meningitidis, Neisseria gonorrhea, Pseudomonas fluorescens, Pseudomonas chiororaphis, Xylella fastidiosa and Vibrio parahaemolyticus.
11. The composition of claim 10 , wherein the cupredoxin is from Pseudomonas aeruginosa or Neisseria gonorrhea.
12. A method to treat a patient infected with HIV-1, comprising administering to the patient a therapeutically effective amount of the composition of claim 8 .
13. The method of claim 12 , wherein the patient is human.
14. The method of claim 12 , wherein the composition is administered by a mode selected from the group consisting of intravenous injection, intramuscular injection, subcutaneous injection, inhalation, topical administration, transdermal patch, suppository and oral.
15. The method of claim 14 , wherein the mode of administration is by intravenous injection.
16. The method of claim 12 , wherein the composition is administered within 0 minutes to 1 week of the administration of another anti-HIV drug.
17. The method of claim 16 , wherein the composition is administered at about the same time as another anti-HIV drug.
18. A kit comprising the composition of claim 8 in a vial.
19. The kit of claim 18 , wherein the kit is designed for intravenous administration.
20. An isolated peptide consisting of residues 36-128 of SEQ ID NO:1, wherein the peptide is capable of binding to one or more targets selected from the group consisting of CD4, ICAM3 and DC-SIGN with an equal or greater affinity than the affinity of gp120 for the same one or more targets.
21. The isolated peptide of claim 7 , wherein residues 36-128 of SEQ ID NO:1 are fused with SEQ ID NO:18.
22. The isolated peptide of claim 1 , wherein the peptide is chemically modified by amidation, acetylation, sulfation, polyethylene glycol (PEG) modification, phosphorylation or glycosylation.
23. The isolated peptide of claim 1 , wherein the peptide is fused to a drug molecule, a therapeutic agent, a pharmaceutical agent, another peptide, or a detectable probe.